Non-pharmaceutical interventions to optimize cancer immunotherapy

The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one's own vulnerability and mortality might be counterproductive and not doing justice to the complexity of human nature. Unlike...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 12; no. 1; p. 2255459
Main Authors Boesch, Maximilian, Baty, Florent, Rassouli, Frank, Kowatsch, Tobias, Joerger, Markus, Früh, Martin, Brutsche, Martin H.
Format Journal Article
LanguageEnglish
Published Taylor & Francis 31.12.2023
Taylor & Francis Group
Subjects
Cancer immunotherapy
circadian rhythm
diet
digital therapeutics
microbiome
physical activity
Review
stress management
telemedicine
Online AccessGet full text

Cover

Abstract The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one's own vulnerability and mortality might be counterproductive and not doing justice to the complexity of human nature. Unlike cytotoxic and lympho-depleting treatments, immune-engaging therapies strengthen the immune system and are typically less harmful for patients. Thus, cancer patients receiving checkpoint inhibitors are not viewed as being vulnerable per se, at least not in immunological and physical terms. This perspective article advocates a holistic approach to cancer immunotherapy, with an empowered patient in the center, focusing on personal resources and receiving domain-specific support from healthcare professionals. It summarizes recent evidence on non-pharmaceutical interventions to enhance the efficacy of immune checkpoint blockade and improve quality of life. These interventions target behavioral factors such as diet, physical activity, stress management, circadian timing of checkpoint inhibitor infusion, and waiving unnecessary co-medication curtailing immunotherapy efficacy. Non-pharmaceutical interventions are universally accessible, broadly applicable, instantly actionable, scalable, and economically sustainable, creating value for all stakeholders involved. Most importantly, this holistic framework re-emphasizes the patient as a whole and harnesses the full potential of anticancer immunity and checkpoint blockade, potentially leading to survival benefits. Digital therapeutics are proposed to accompany the patients on their mission toward change in lifestyle-related behaviors for creating optimal conditions for treatment efficacy and personal growth.
AbstractList ABSTRACTThe traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one’s own vulnerability and mortality might be counterproductive and not doing justice to the complexity of human nature. Unlike cytotoxic and lympho-depleting treatments, immune-engaging therapies strengthen the immune system and are typically less harmful for patients. Thus, cancer patients receiving checkpoint inhibitors are not viewed as being vulnerable per se, at least not in immunological and physical terms. This perspective article advocates a holistic approach to cancer immunotherapy, with an empowered patient in the center, focusing on personal resources and receiving domain-specific support from healthcare professionals. It summarizes recent evidence on non-pharmaceutical interventions to enhance the efficacy of immune checkpoint blockade and improve quality of life. These interventions target behavioral factors such as diet, physical activity, stress management, circadian timing of checkpoint inhibitor infusion, and waiving unnecessary co-medication curtailing immunotherapy efficacy. Non-pharmaceutical interventions are universally accessible, broadly applicable, instantly actionable, scalable, and economically sustainable, creating value for all stakeholders involved. Most importantly, this holistic framework re-emphasizes the patient as a whole and harnesses the full potential of anticancer immunity and checkpoint blockade, potentially leading to survival benefits. Digital therapeutics are proposed to accompany the patients on their mission toward change in lifestyle-related behaviors for creating optimal conditions for treatment efficacy and personal growth.
The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one’s own vulnerability and mortality might be counterproductive and not doing justice to the complexity of human nature. Unlike cytotoxic and lympho-depleting treatments, immune-engaging therapies strengthen the immune system and are typically less harmful for patients. Thus, cancer patients receiving checkpoint inhibitors are not viewed as being vulnerable per se , at least not in immunological and physical terms. This perspective article advocates a holistic approach to cancer immunotherapy, with an empowered patient in the center, focusing on personal resources and receiving domain-specific support from healthcare professionals. It summarizes recent evidence on non-pharmaceutical interventions to enhance the efficacy of immune checkpoint blockade and improve quality of life. These interventions target behavioral factors such as diet, physical activity, stress management, circadian timing of checkpoint inhibitor infusion, and waiving unnecessary co-medication curtailing immunotherapy efficacy. Non-pharmaceutical interventions are universally accessible, broadly applicable, instantly actionable, scalable, and economically sustainable, creating value for all stakeholders involved. Most importantly, this holistic framework re-emphasizes the patient as a whole and harnesses the full potential of anticancer immunity and checkpoint blockade, potentially leading to survival benefits. Digital therapeutics are proposed to accompany the patients on their mission toward change in lifestyle-related behaviors for creating optimal conditions for treatment efficacy and personal growth.
The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one's own vulnerability and mortality might be counterproductive and not doing justice to the complexity of human nature. Unlike cytotoxic and lympho-depleting treatments, immune-engaging therapies strengthen the immune system and are typically less harmful for patients. Thus, cancer patients receiving checkpoint inhibitors are not viewed as being vulnerable per se, at least not in immunological and physical terms. This perspective article advocates a holistic approach to cancer immunotherapy, with an empowered patient in the center, focusing on personal resources and receiving domain-specific support from healthcare professionals. It summarizes recent evidence on non-pharmaceutical interventions to enhance the efficacy of immune checkpoint blockade and improve quality of life. These interventions target behavioral factors such as diet, physical activity, stress management, circadian timing of checkpoint inhibitor infusion, and waiving unnecessary co-medication curtailing immunotherapy efficacy. Non-pharmaceutical interventions are universally accessible, broadly applicable, instantly actionable, scalable, and economically sustainable, creating value for all stakeholders involved. Most importantly, this holistic framework re-emphasizes the patient as a whole and harnesses the full potential of anticancer immunity and checkpoint blockade, potentially leading to survival benefits. Digital therapeutics are proposed to accompany the patients on their mission toward change in lifestyle-related behaviors for creating optimal conditions for treatment efficacy and personal growth.
Author Rassouli, Frank
Baty, Florent
Kowatsch, Tobias
Boesch, Maximilian
Joerger, Markus
Früh, Martin
Brutsche, Martin H.
Author_xml – sequence: 1
  givenname: Maximilian
  orcidid: 0000-0002-0994-9883
  surname: Boesch
  fullname: Boesch, Maximilian
  email: maximilian.boesch@kssg.ch
  organization: Cantonal Hospital St.Gallen
– sequence: 2
  givenname: Florent
  surname: Baty
  fullname: Baty, Florent
  organization: Cantonal Hospital St.Gallen
– sequence: 3
  givenname: Frank
  surname: Rassouli
  fullname: Rassouli, Frank
  organization: Cantonal Hospital St.Gallen
– sequence: 4
  givenname: Tobias
  orcidid: 0000-0001-5939-4145
  surname: Kowatsch
  fullname: Kowatsch, Tobias
  organization: Centre for Digital Health Interventions, Department of Technology, Management, and Economics, ETH Zurich
– sequence: 5
  givenname: Markus
  surname: Joerger
  fullname: Joerger, Markus
  organization: Cantonal Hospital St.Gallen
– sequence: 6
  givenname: Martin
  surname: Früh
  fullname: Früh, Martin
  organization: University Hospital Bern
– sequence: 7
  givenname: Martin H.
  orcidid: 0000-0002-1612-3609
  surname: Brutsche
  fullname: Brutsche, Martin H.
  organization: Cantonal Hospital St.Gallen
BookMark eNp9kctuFDEQRVsoSIQknxCpl2x68LMfK4giHpEi2AQpO6vsLmccdduN7Q4avh4PMyCywRtbt26dKuu-rk588FhVl5RsKOnJW0ZbJgi73zDC-IYxKYUcXlSne73ZF07-eb-qLlJ6JOW0RLZ8OK2uvgTfLFuIMxhcszMw1c5njE_osws-1TnUYcludj-xNuANxtrN8-pD3mKEZXdevbQwJbw43mfVt48f7q4_N7dfP91cX902RlKWG9CjQdkJZu2oO2I4Wm6Flm03gJYdtC0tuzPL-1YWG_RIByziKOgwamT8rLo5cMcAj2qJboa4UwGc-i2E-KAglg9MqAxtqQYxcgtEiN7ollPsLCNCWzQGCuvdgbWsesaymM8RpmfQ5xXvtuohPClKpOBcdIXw5kiI4fuKKavZJYPTBB7DmhTrO9YTSbksVnmwmhhSimj_zqFE7TNUfzJU-wzVMcPS9_7Q57wNJZ8fIU6jyrCbQrSxJOGS4v9H_AKvcadq
CitedBy_id crossref_primary_10_1016_j_ejim_2024_03_025
crossref_primary_10_1038_s41416_024_02704_9
crossref_primary_10_3389_fonc_2023_1284089
Cites_doi 10.1093/aje/kwq447
10.3389/fpsyg.2019.02418
10.2196/40789
10.1186/s12885-022-10296-x
10.1007/s12599-023-00804-z
10.1016/j.ccell.2022.05.006
10.1037/0033-2909.130.4.601
10.1038/s41416-021-01365-2
10.1080/0284186X.2020.1817550
10.1634/theoncologist.2014-0381
10.1097/HRP.0000000000000277
10.1056/NEJMoa1003466
10.3389/fimmu.2021.624434
10.1073/pnas.1908158117
10.1126/science.aan4236
10.1126/science.1208344
10.1007/s10916-022-01899-9
10.1001/jama.2012.14641
10.2196/28703
10.1016/S2589-7500(21)00292-2
10.1136/jitc-2022-005401
10.3389/fonc.2020.01492
10.1016/j.ejca.2015.11.016
10.1371/journal.pdig.0000104
10.1177/1559827617729634
10.1016/j.isci.2020.100978
10.1038/s41579-022-00820-y
10.1002/eji.202250183
10.1016/j.cmet.2022.02.004
10.1001/jamainternmed.2016.1548
10.1016/j.jtho.2019.04.007
10.1186/s12966-019-0792-7
10.2196/39243
10.1016/j.pmedr.2020.101299
10.2196/15178
10.1016/j.cell.2021.06.019
10.1038/nrc3829
10.3390/nu11050977
10.1001/jama.2014.14781
10.1158/2326-6066.CIR-20-0445
10.3389/fdgth.2023.1039171
10.1016/j.ejca.2022.05.046
10.1016/j.immuni.2016.12.011
10.1126/science.aan3706
10.2196/18819
10.1038/s41591-019-0566-4
10.1136/bmjopen-2016-012447
10.1111/jcpt.13469
10.1097/PSY.0000000000001027
10.1038/s41579-022-00805-x
10.1002/pon.3067
10.1038/nature12820
10.1038/s41746-023-00777-z
10.1177/1745691621989243
10.1177/1090198117712333
10.1186/s12889-019-7407-8
10.1038/d41586-022-02355-x
10.1056/NEJMoa1716078
10.1016/j.invent.2022.100501
10.18632/oncotarget.2053
10.1038/nature13398
10.1371/journal.pbio.1002533
10.1093/abm/kaad041
10.1002/cncr.34467
10.1136/jitc-2021-003388
10.1186/s12889-016-3803-5
10.1002/cncr.34012
10.1016/j.ccell.2022.02.014
10.1136/bjsports-2015-094787
10.1080/2162402X.2017.1414129
10.1016/j.vaccine.2016.04.032
10.1080/2162402X.2021.1988403
10.1007/s12160-016-9830-8
10.1080/23723556.2020.1868266
10.1136/jitc-2021-003477
10.1016/S0140-6736(22)01438-6
10.1136/jitc-2022-005646
10.1186/s13073-019-0704-0
10.1038/s41576-022-00519-z
10.1136/bmjopen-2019-036059
10.1038/s41467-021-27349-7
10.1038/nature13954
10.1016/S0140-6736(21)00313-5
10.1016/S1470-2045(21)00546-5
10.1136/bmj.l5784
10.1016/j.ctrv.2007.01.005
10.1177/1742395313495572
10.1038/s41571-023-00734-5
10.3389/fpubh.2021.625640
10.1001/jamaoncol.2019.5570
10.1126/science.aaz7015
10.1038/s41416-020-01060-8
10.1136/jitc-2020-001383
10.1038/s41467-020-16890-6
10.1002/hsr2.1157
10.1093/neuonc/noab046
10.1002/pon.4692
10.2196/21088
10.2196/41425
10.1001/jamanetworkopen.2020.15633
10.1136/postgradmedj-2018-135719
10.1002/cncr.34046
10.1126/science.aad1329
10.1016/S2589-7500(22)00111-X
10.1016/j.bcp.2020.114045
10.1016/j.puhe.2016.03.030
10.1172/jci.insight.145207
10.1377/hlthaff.2018.05081
10.1371/journal.pone.0154496
10.1126/sciimmunol.abm2465
10.1016/j.cell.2022.07.020
10.1016/j.jcbs.2019.06.002
10.3389/fimmu.2019.01402
10.1002/cncr.31394
10.1038/s41598-022-12964-1
10.2196/33348
10.1158/2159-8290.CD-21-0030
10.1158/1541-7786.MCR-21-0786
10.1007/s00280-019-03993-1
10.1056/NEJMoa1809944
10.1200/JCO.2020.38.15_suppl.e15234
10.1016/j.cell.2021.09.019
10.1016/j.ccell.2021.11.002
10.1186/s40425-019-0805-8
10.1002/ijc.31186
10.1093/abm/kaaa002
10.1126/science.abb5920
10.1016/j.ctrv.2018.05.016
10.1007/978-3-030-76897-3_4
10.2147/JMDH.S117945
10.1038/s41467-023-35979-2
10.1016/j.brainres.2021.147309
10.3389/fimmu.2022.977525
10.1158/2326-6066.CIR-20-0396
10.1158/1055-9965.EPI-21-0508
10.1056/NEJMoa1912400
10.1016/j.ejca.2018.10.014
10.1038/s41590-020-0793-3
10.1126/scitranslmed.abb5817
10.3389/fimmu.2022.989000
10.1158/2159-8290.CD-21-0900
10.1080/2162402X.2019.1591878
10.1056/NEJMoa2202170
10.2196/43227
10.1146/annurev.immunol.22.012703.104803
10.1172/JCI129317
10.1038/s41591-022-01965-2
10.1016/B978-0-323-90045-4.00008-3
10.1249/MSS.0000000000002828
10.1200/JCO.2010.28.4455
10.1038/s41422-021-00541-6
10.1016/j.annonc.2022.05.010
10.3390/cancers14040896
10.1038/nri1936
10.1016/j.molcel.2021.03.037
10.1093/annonc/mdy103
10.1001/jamanetworkopen.2022.0448
10.1097/00006842-199201000-00005
10.3390/ijerph17165930
10.1002/cncr.34718
10.1038/ismej.2016.13
10.1249/MSS.0000000000001937
10.1001/jamaoncol.2019.0402
10.1016/j.cell.2020.11.009
10.1126/science.1198719
10.1172/JCI133934
10.1126/scitranslmed.aay8707
10.1371/journal.pone.0218048
10.2196/39186
10.1038/s41586-022-04875-y
ContentType Journal Article
Copyright 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023
2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s)
Copyright_xml – notice: 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023
– notice: 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 The Author(s)
DBID 0YH
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1080/2162402X.2023.2255459
DatabaseName Taylor & Francis Open Access Journals
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 0YH
  name: Taylor & Francis Open Access Journals
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate M. BOESCH ET AL
EISSN 2162-402X
EndPage 2255459
ExternalDocumentID oai_doaj_org_article_c161ba4d3fa0448cb631e7f204bfecca
10_1080_2162402X_2023_2255459
2255459
Genre Review
GrantInformation_xml – fundername: The author(s) reported there is no funding associated
GroupedDBID 00X
0R~
0YH
53G
AAKDD
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
ADFCX
ADING
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BABNJ
BLEHA
CCCUG
EBS
EUPTU
GROUPED_DOAJ
KRBQP
KSSTO
KTTOD
KWAYT
KYCEM
LJTGL
O9-
OK1
RPM
TFL
TFW
UHWXJ
ZA5
AAYXX
CITATION
H13
TDBHL
7X8
DGEBU
DGFLZ
HYE
M4Z
5PM
ID FETCH-LOGICAL-c512t-abdce5742ffdb70c3ef3f4b5679ab57a6612552f3865574a8e19e661d419dbe23
IEDL.DBID RPM
ISSN 2162-402X
2162-4011
IngestDate Tue Oct 22 15:16:02 EDT 2024
Tue Sep 17 21:29:36 EDT 2024
Sat Aug 17 01:35:13 EDT 2024
Fri Aug 23 03:06:03 EDT 2024
Thu Jan 04 07:16:41 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License open-access: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c512t-abdce5742ffdb70c3ef3f4b5679ab57a6612552f3865574a8e19e661d419dbe23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0001-5939-4145
0000-0002-1612-3609
0000-0002-0994-9883
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543347/
PQID 2872805135
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_c161ba4d3fa0448cb631e7f204bfecca
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10543347
informaworld_taylorfrancis_310_1080_2162402X_2023_2255459
proquest_miscellaneous_2872805135
crossref_primary_10_1080_2162402X_2023_2255459
PublicationCentury 2000
PublicationDate 2023-12-31
PublicationDateYYYYMMDD 2023-12-31
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-31
  day: 31
PublicationDecade 2020
PublicationTitle Oncoimmunology
PublicationYear 2023
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_6_30_1
e_1_3_6_53_1
e_1_3_6_76_1
e_1_3_6_99_1
e_1_3_6_117_1
e_1_3_6_11_1
e_1_3_6_72_1
e_1_3_6_95_1
e_1_3_6_113_1
e_1_3_6_136_1
e_1_3_6_91_1
e_1_3_6_155_1
e_1_3_6_132_1
e_1_3_6_151_1
e_1_3_6_174_1
e_1_3_6_15_1
e_1_3_6_38_1
e_1_3_6_19_1
e_1_3_6_34_1
e_1_3_6_57_1
e_1_3_6_42_1
e_1_3_6_65_1
e_1_3_6_88_1
e_1_3_6_128_1
e_1_3_6_109_1
e_1_3_6_2_1
e_1_3_6_61_1
e_1_3_6_124_1
Long JE (e_1_3_6_84_1) 2016; 34
e_1_3_6_105_1
e_1_3_6_147_1
e_1_3_6_6_1
e_1_3_6_80_1
e_1_3_6_120_1
e_1_3_6_166_1
e_1_3_6_101_1
e_1_3_6_143_1
e_1_3_6_162_1
e_1_3_6_27_1
e_1_3_6_23_1
e_1_3_6_46_1
e_1_3_6_69_1
e_1_3_6_118_1
e_1_3_6_52_1
e_1_3_6_98_1
e_1_3_6_33_1
e_1_3_6_75_1
e_1_3_6_114_1
e_1_3_6_137_1
e_1_3_6_10_1
e_1_3_6_94_1
e_1_3_6_71_1
e_1_3_6_110_1
e_1_3_6_133_1
e_1_3_6_156_1
e_1_3_6_90_1
e_1_3_6_152_1
e_1_3_6_171_1
e_1_3_6_175_1
e_1_3_6_14_1
e_1_3_6_18_1
e_1_3_6_56_1
e_1_3_6_37_1
e_1_3_6_79_1
e_1_3_6_106_1
e_1_3_6_129_1
e_1_3_6_41_1
e_1_3_6_87_1
Martin-Ruiz A (e_1_3_6_47_1) 2020; 26
e_1_3_6_22_1
e_1_3_6_64_1
e_1_3_6_102_1
e_1_3_6_125_1
e_1_3_6_148_1
e_1_3_6_83_1
e_1_3_6_121_1
e_1_3_6_144_1
e_1_3_6_167_1
e_1_3_6_3_1
Gallant MP (e_1_3_6_159_1) 2013
e_1_3_6_140_1
e_1_3_6_163_1
e_1_3_6_7_1
e_1_3_6_170_1
e_1_3_6_49_1
Chen Y (e_1_3_6_60_1) 2022; 12
e_1_3_6_45_1
e_1_3_6_26_1
e_1_3_6_68_1
e_1_3_6_32_1
e_1_3_6_55_1
e_1_3_6_74_1
e_1_3_6_97_1
e_1_3_6_119_1
e_1_3_6_138_1
e_1_3_6_51_1
e_1_3_6_70_1
e_1_3_6_93_1
e_1_3_6_115_1
e_1_3_6_157_1
e_1_3_6_134_1
e_1_3_6_111_1
e_1_3_6_153_1
e_1_3_6_130_1
e_1_3_6_172_1
e_1_3_6_13_1
e_1_3_6_17_1
e_1_3_6_36_1
e_1_3_6_59_1
e_1_3_6_78_1
e_1_3_6_107_1
e_1_3_6_21_1
e_1_3_6_44_1
e_1_3_6_63_1
e_1_3_6_86_1
e_1_3_6_103_1
e_1_3_6_149_1
e_1_3_6_40_1
e_1_3_6_82_1
e_1_3_6_126_1
e_1_3_6_168_1
e_1_3_6_145_1
e_1_3_6_4_1
e_1_3_6_122_1
e_1_3_6_164_1
e_1_3_6_141_1
e_1_3_6_8_1
e_1_3_6_160_1
e_1_3_6_29_1
e_1_3_6_25_1
e_1_3_6_48_1
e_1_3_6_67_1
e_1_3_6_31_1
e_1_3_6_77_1
e_1_3_6_139_1
e_1_3_6_54_1
e_1_3_6_96_1
e_1_3_6_73_1
e_1_3_6_116_1
e_1_3_6_135_1
e_1_3_6_158_1
e_1_3_6_50_1
e_1_3_6_92_1
e_1_3_6_112_1
e_1_3_6_131_1
e_1_3_6_154_1
e_1_3_6_150_1
e_1_3_6_173_1
e_1_3_6_39_1
e_1_3_6_12_1
e_1_3_6_35_1
e_1_3_6_16_1
e_1_3_6_58_1
e_1_3_6_20_1
e_1_3_6_66_1
e_1_3_6_108_1
e_1_3_6_43_1
e_1_3_6_85_1
e_1_3_6_62_1
e_1_3_6_81_1
e_1_3_6_104_1
e_1_3_6_127_1
e_1_3_6_146_1
e_1_3_6_169_1
e_1_3_6_5_1
e_1_3_6_100_1
e_1_3_6_123_1
e_1_3_6_142_1
e_1_3_6_165_1
e_1_3_6_9_1
e_1_3_6_161_1
e_1_3_6_28_1
e_1_3_6_24_1
e_1_3_6_89_1
References_xml – ident: e_1_3_6_107_1
  doi: 10.1093/aje/kwq447
– ident: e_1_3_6_148_1
  doi: 10.3389/fpsyg.2019.02418
– ident: e_1_3_6_134_1
  doi: 10.2196/40789
– ident: e_1_3_6_122_1
  doi: 10.1186/s12885-022-10296-x
– ident: e_1_3_6_127_1
  doi: 10.1007/s12599-023-00804-z
– ident: e_1_3_6_45_1
  doi: 10.1016/j.ccell.2022.05.006
– ident: e_1_3_6_57_1
  doi: 10.1037/0033-2909.130.4.601
– ident: e_1_3_6_3_1
  doi: 10.1038/s41416-021-01365-2
– ident: e_1_3_6_49_1
  doi: 10.1080/0284186X.2020.1817550
– ident: e_1_3_6_111_1
  doi: 10.1634/theoncologist.2014-0381
– ident: e_1_3_6_143_1
  doi: 10.1097/HRP.0000000000000277
– ident: e_1_3_6_2_1
  doi: 10.1056/NEJMoa1003466
– ident: e_1_3_6_21_1
  doi: 10.3389/fimmu.2021.624434
– ident: e_1_3_6_115_1
  doi: 10.1073/pnas.1908158117
– ident: e_1_3_6_39_1
  doi: 10.1126/science.aan4236
– ident: e_1_3_6_7_1
  doi: 10.1126/science.1208344
– ident: e_1_3_6_133_1
  doi: 10.1007/s10916-022-01899-9
– ident: e_1_3_6_106_1
  doi: 10.1001/jama.2012.14641
– ident: e_1_3_6_142_1
  doi: 10.2196/28703
– ident: e_1_3_6_172_1
  doi: 10.1016/S2589-7500(21)00292-2
– ident: e_1_3_6_4_1
  doi: 10.1136/jitc-2022-005401
– volume: 12
  start-page: 5286
  issue: 11
  year: 2022
  ident: e_1_3_6_60_1
  article-title: Chronic stress promotes tumor immune evasion via the suppression of MHC-I expression and the upregulation of PD-L1
  publication-title: Am J Cancer Res
  contributor:
    fullname: Chen Y
– ident: e_1_3_6_61_1
  doi: 10.3389/fonc.2020.01492
– ident: e_1_3_6_98_1
  doi: 10.1016/j.ejca.2015.11.016
– volume: 34
  start-page: 2679
  issue: 40
  year: 2016
  ident: e_1_3_6_84_1
  article-title: Corrigendum to ‘morning vaccination enhances antibody response over afternoon vaccination: a cluster-randomised trial
  publication-title: [Vaccine 34 (2016)
  contributor:
    fullname: Long JE
– ident: e_1_3_6_137_1
  doi: 10.1371/journal.pdig.0000104
– ident: e_1_3_6_145_1
  doi: 10.1177/1559827617729634
– ident: e_1_3_6_48_1
  doi: 10.1016/j.isci.2020.100978
– ident: e_1_3_6_95_1
  doi: 10.1038/s41579-022-00820-y
– ident: e_1_3_6_22_1
  doi: 10.1002/eji.202250183
– ident: e_1_3_6_35_1
  doi: 10.1016/j.cmet.2022.02.004
– ident: e_1_3_6_42_1
  doi: 10.1001/jamainternmed.2016.1548
– ident: e_1_3_6_40_1
  doi: 10.1016/j.jtho.2019.04.007
– ident: e_1_3_6_129_1
  doi: 10.1186/s12966-019-0792-7
– ident: e_1_3_6_136_1
  doi: 10.2196/39243
– ident: e_1_3_6_160_1
  doi: 10.1016/j.pmedr.2020.101299
– ident: e_1_3_6_170_1
  doi: 10.2196/15178
– ident: e_1_3_6_13_1
  doi: 10.1016/j.cell.2021.06.019
– ident: e_1_3_6_29_1
  doi: 10.1038/nrc3829
– ident: e_1_3_6_112_1
  doi: 10.3390/nu11050977
– ident: e_1_3_6_139_1
  doi: 10.1001/jama.2014.14781
– ident: e_1_3_6_68_1
  doi: 10.1158/2326-6066.CIR-20-0445
– ident: e_1_3_6_154_1
  doi: 10.3389/fdgth.2023.1039171
– ident: e_1_3_6_27_1
  doi: 10.1016/j.ejca.2022.05.046
– ident: e_1_3_6_79_1
  doi: 10.1016/j.immuni.2016.12.011
– ident: e_1_3_6_93_1
  doi: 10.1126/science.aan3706
– ident: e_1_3_6_169_1
  doi: 10.2196/18819
– ident: e_1_3_6_66_1
  doi: 10.1038/s41591-019-0566-4
– ident: e_1_3_6_150_1
  doi: 10.1136/bmjopen-2016-012447
– ident: e_1_3_6_99_1
  doi: 10.1111/jcpt.13469
– ident: e_1_3_6_62_1
  doi: 10.1097/PSY.0000000000001027
– ident: e_1_3_6_10_1
  doi: 10.1038/s41579-022-00805-x
– ident: e_1_3_6_63_1
  doi: 10.1002/pon.3067
– ident: e_1_3_6_9_1
  doi: 10.1038/nature12820
– ident: e_1_3_6_126_1
  doi: 10.1038/s41746-023-00777-z
– ident: e_1_3_6_56_1
  doi: 10.1177/1745691621989243
– ident: e_1_3_6_161_1
  doi: 10.1177/1090198117712333
– ident: e_1_3_6_153_1
  doi: 10.1186/s12889-019-7407-8
– ident: e_1_3_6_158_1
  doi: 10.1038/d41586-022-02355-x
– ident: e_1_3_6_104_1
  doi: 10.1056/NEJMoa1716078
– ident: e_1_3_6_131_1
  doi: 10.1016/j.invent.2022.100501
– ident: e_1_3_6_70_1
  doi: 10.18632/oncotarget.2053
– ident: e_1_3_6_24_1
  doi: 10.1038/nature13398
– ident: e_1_3_6_6_1
  doi: 10.1371/journal.pbio.1002533
– ident: e_1_3_6_162_1
  doi: 10.1093/abm/kaad041
– ident: e_1_3_6_5_1
  doi: 10.1002/cncr.34467
– ident: e_1_3_6_46_1
  doi: 10.1136/jitc-2021-003388
– ident: e_1_3_6_163_1
  doi: 10.1186/s12889-016-3803-5
– ident: e_1_3_6_168_1
  doi: 10.1002/cncr.34012
– ident: e_1_3_6_19_1
  doi: 10.1016/j.ccell.2022.02.014
– ident: e_1_3_6_50_1
  doi: 10.1136/bjsports-2015-094787
– ident: e_1_3_6_72_1
  doi: 10.1080/2162402X.2017.1414129
– ident: e_1_3_6_83_1
  doi: 10.1016/j.vaccine.2016.04.032
– ident: e_1_3_6_17_1
  doi: 10.1080/2162402X.2021.1988403
– ident: e_1_3_6_128_1
  doi: 10.1007/s12160-016-9830-8
– ident: e_1_3_6_32_1
  doi: 10.1080/23723556.2020.1868266
– ident: e_1_3_6_116_1
  doi: 10.1136/jitc-2021-003477
– ident: e_1_3_6_157_1
  doi: 10.1016/S0140-6736(22)01438-6
– ident: e_1_3_6_102_1
  doi: 10.1136/jitc-2022-005646
– ident: e_1_3_6_69_1
  doi: 10.1186/s13073-019-0704-0
– ident: e_1_3_6_76_1
  doi: 10.1038/s41576-022-00519-z
– ident: e_1_3_6_52_1
  doi: 10.1136/bmjopen-2019-036059
– ident: e_1_3_6_67_1
  doi: 10.1038/s41467-021-27349-7
– ident: e_1_3_6_44_1
  doi: 10.1038/nature13954
– ident: e_1_3_6_96_1
  doi: 10.1016/S0140-6736(21)00313-5
– ident: e_1_3_6_86_1
  doi: 10.1016/S1470-2045(21)00546-5
– ident: e_1_3_6_54_1
  doi: 10.1136/bmj.l5784
– ident: e_1_3_6_110_1
  doi: 10.1016/j.ctrv.2007.01.005
– ident: e_1_3_6_146_1
  doi: 10.1177/1742395313495572
– ident: e_1_3_6_30_1
  doi: 10.1038/s41571-023-00734-5
– ident: e_1_3_6_155_1
  doi: 10.3389/fpubh.2021.625640
– ident: e_1_3_6_92_1
  doi: 10.1001/jamaoncol.2019.5570
– ident: e_1_3_6_36_1
  doi: 10.1126/science.aaz7015
– ident: e_1_3_6_109_1
  doi: 10.1038/s41416-020-01060-8
– ident: e_1_3_6_18_1
  doi: 10.1136/jitc-2020-001383
– ident: e_1_3_6_74_1
  doi: 10.1038/s41467-020-16890-6
– ident: e_1_3_6_141_1
  doi: 10.1002/hsr2.1157
– ident: e_1_3_6_101_1
  doi: 10.1093/neuonc/noab046
– ident: e_1_3_6_175_1
  doi: 10.1002/pon.4692
– ident: e_1_3_6_166_1
  doi: 10.2196/21088
– ident: e_1_3_6_167_1
  doi: 10.2196/41425
– ident: e_1_3_6_140_1
  doi: 10.1001/jamanetworkopen.2020.15633
– ident: e_1_3_6_75_1
  doi: 10.1136/postgradmedj-2018-135719
– ident: e_1_3_6_171_1
  doi: 10.1002/cncr.34046
– ident: e_1_3_6_16_1
  doi: 10.1126/science.aad1329
– ident: e_1_3_6_138_1
  doi: 10.1016/S2589-7500(22)00111-X
– ident: e_1_3_6_77_1
  doi: 10.1016/j.bcp.2020.114045
– ident: e_1_3_6_124_1
  doi: 10.1016/j.puhe.2016.03.030
– ident: e_1_3_6_33_1
  doi: 10.1172/jci.insight.145207
– ident: e_1_3_6_165_1
  doi: 10.1377/hlthaff.2018.05081
– ident: e_1_3_6_53_1
  doi: 10.1371/journal.pone.0154496
– ident: e_1_3_6_78_1
  doi: 10.1126/sciimmunol.abm2465
– ident: e_1_3_6_11_1
  doi: 10.1016/j.cell.2022.07.020
– ident: e_1_3_6_144_1
  doi: 10.1016/j.jcbs.2019.06.002
– ident: e_1_3_6_28_1
  doi: 10.3389/fimmu.2019.01402
– ident: e_1_3_6_174_1
  doi: 10.1002/cncr.31394
– ident: e_1_3_6_149_1
  doi: 10.1038/s41598-022-12964-1
– ident: e_1_3_6_164_1
  doi: 10.2196/33348
– ident: e_1_3_6_26_1
  doi: 10.1158/2159-8290.CD-21-0030
– ident: e_1_3_6_88_1
  doi: 10.1158/1541-7786.MCR-21-0786
– ident: e_1_3_6_94_1
  doi: 10.1007/s00280-019-03993-1
– ident: e_1_3_6_108_1
  doi: 10.1056/NEJMoa1809944
– ident: e_1_3_6_100_1
  doi: 10.1200/JCO.2020.38.15_suppl.e15234
– ident: e_1_3_6_38_1
  doi: 10.1016/j.cell.2021.09.019
– ident: e_1_3_6_123_1
  doi: 10.1016/j.ccell.2021.11.002
– ident: e_1_3_6_90_1
  doi: 10.1186/s40425-019-0805-8
– ident: e_1_3_6_71_1
  doi: 10.1002/ijc.31186
– ident: e_1_3_6_147_1
  doi: 10.1093/abm/kaaa002
– ident: e_1_3_6_15_1
  doi: 10.1126/science.abb5920
– ident: e_1_3_6_117_1
  doi: 10.1016/j.ctrv.2018.05.016
– ident: e_1_3_6_130_1
  doi: 10.1007/978-3-030-76897-3_4
– ident: e_1_3_6_173_1
  doi: 10.2147/JMDH.S117945
– ident: e_1_3_6_80_1
  doi: 10.1038/s41467-023-35979-2
– ident: e_1_3_6_152_1
  doi: 10.1016/j.brainres.2021.147309
– ident: e_1_3_6_82_1
  doi: 10.3389/fimmu.2022.977525
– ident: e_1_3_6_25_1
  doi: 10.1158/2326-6066.CIR-20-0396
– ident: e_1_3_6_43_1
  doi: 10.1158/1055-9965.EPI-21-0508
– ident: e_1_3_6_97_1
  doi: 10.1056/NEJMoa1912400
– ident: e_1_3_6_91_1
  doi: 10.1016/j.ejca.2018.10.014
– ident: e_1_3_6_121_1
  doi: 10.1038/s41590-020-0793-3
– ident: e_1_3_6_64_1
  doi: 10.1126/scitranslmed.abb5817
– ident: e_1_3_6_113_1
  doi: 10.3389/fimmu.2022.989000
– volume: 26
  start-page: 100
  year: 2020
  ident: e_1_3_6_47_1
  article-title: Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma
  publication-title: Exerc Immunol Rev
  contributor:
    fullname: Martin-Ruiz A
– ident: e_1_3_6_118_1
  doi: 10.1158/2159-8290.CD-21-0900
– ident: e_1_3_6_20_1
  doi: 10.1080/2162402X.2019.1591878
– ident: e_1_3_6_105_1
  doi: 10.1056/NEJMoa2202170
– ident: e_1_3_6_135_1
  doi: 10.2196/43227
– ident: e_1_3_6_59_1
  doi: 10.1146/annurev.immunol.22.012703.104803
– ident: e_1_3_6_120_1
  doi: 10.1172/JCI129317
– ident: e_1_3_6_37_1
  doi: 10.1038/s41591-022-01965-2
– ident: e_1_3_6_125_1
  doi: 10.1016/B978-0-323-90045-4.00008-3
– ident: e_1_3_6_51_1
  doi: 10.1249/MSS.0000000000002828
– ident: e_1_3_6_65_1
  doi: 10.1200/JCO.2010.28.4455
– ident: e_1_3_6_85_1
  doi: 10.1038/s41422-021-00541-6
– ident: e_1_3_6_103_1
  doi: 10.1016/j.annonc.2022.05.010
– ident: e_1_3_6_87_1
  doi: 10.3390/cancers14040896
– ident: e_1_3_6_58_1
  doi: 10.1038/nri1936
– ident: e_1_3_6_34_1
  doi: 10.1016/j.molcel.2021.03.037
– ident: e_1_3_6_14_1
  doi: 10.1093/annonc/mdy103
– ident: e_1_3_6_31_1
  doi: 10.1001/jamanetworkopen.2022.0448
– ident: e_1_3_6_55_1
  doi: 10.1097/00006842-199201000-00005
– ident: e_1_3_6_132_1
  doi: 10.3390/ijerph17165930
– ident: e_1_3_6_119_1
  doi: 10.1002/cncr.34718
– ident: e_1_3_6_12_1
  doi: 10.1038/ismej.2016.13
– ident: e_1_3_6_41_1
  doi: 10.1249/MSS.0000000000001937
– ident: e_1_3_6_89_1
  doi: 10.1001/jamaoncol.2019.0402
– ident: e_1_3_6_23_1
  doi: 10.1016/j.cell.2020.11.009
– start-page: 0
  volume-title: The Oxford Handbook of Health Communication, behavior change, and treatment adherence
  year: 2013
  ident: e_1_3_6_159_1
  contributor:
    fullname: Gallant MP
– ident: e_1_3_6_8_1
  doi: 10.1126/science.1198719
– ident: e_1_3_6_81_1
  doi: 10.1172/JCI133934
– ident: e_1_3_6_114_1
  doi: 10.1126/scitranslmed.aay8707
– ident: e_1_3_6_156_1
  doi: 10.1371/journal.pone.0218048
– ident: e_1_3_6_151_1
  doi: 10.2196/39186
– ident: e_1_3_6_73_1
  doi: 10.1038/s41586-022-04875-y
SSID ssj0000605639
Score 2.3969123
SecondaryResourceType review_article
Snippet The traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical...
ABSTRACTThe traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the...
SourceID doaj
pubmedcentral
proquest
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Publisher
StartPage 2255459
SubjectTerms Cancer immunotherapy
circadian rhythm
diet
digital therapeutics
microbiome
physical activity
Review
stress management
telemedicine
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07a8MwEBYlUOhS-qTpCxe6OpGsh60xLQ2h0EwNZBOSI5EMtUPiDOmv78mPYnfJ0tUW9vlOvvtO0n2H0LPwu1sJNWGMNSQoxLpQUh2FkSVGC4ZNQnyh8MdUTGbsfc7nrVZf_kxYRQ9cKW6YAiQxmi2o0xhSidQISmzsIsyM868vvS-WrWSq8sEQ2KlsSnYSPIyI8BsJ84HvFz6AWQzQQXaCUcnZ_4extIM7u6cmW2FofIZOa_wYjCq5z9GRzS7QcdVRcn-JRtM8C9fL9jp1sGoda9wGRR7k4Ca-Vt82SL3JN8HK14jUlVj7KzQbv32-TsK6S0KYQrAuQm1AIg4ZrnMLE-OUWkcdM1zEUhsea-ExDI-cb-4Jw3RiibRwccGIXBgb0WvUy_LM3qAACy0xSyXHxjDOnQS0whk8WcqUEJH00aBRl1pXZBiK1ByjjX6V16-q9dtHL16pv4M9l3V5ASysagurQxbuI9k2iSrKpQxX9R1R9IAAT439FPw3fjNEZzbfbRVkilECHonyPko6hu1I272TrZYlAzeAUkYpi2__4_vu0IkXuWKPvEe9YrOzD4B0CvNYTuofGFL7Cw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Taylor & Francis Open Access Journals
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA4-ELyIT1xfVPDaNWkebY4qLougJ4X1FJJu4u7Bdtl2D-uvd9LHshXEg8emaRlmJplvknkgdCP87VZCTRhjDQ4KsS6UVEdhZInRgmGTEJ8o_Pwihm_sacTbaMKiCav0PrSrC0VUe7Vf3NoUbUTcbUSEvxMY9X3r7z4oJKAAuYm2oxisP6g0fh-ujlkwwHUwwm3uzm9fd6xSVbz_R-nSDgDthk-u2aPBPtprgGRwV0v-AG3Y7BDt1K0ll0fo7iXPwtlk_cA6mK7FNxZBmQc57Bef0y8bpF7282Dqk0WalKzlMXobPL4-DMOmXUKYgtUuQ22AIg6urnNjE-OUWkcdM1zEUhsea-HBDI-c7_IJ03RiibQwOGZEjo2N6AnayvLMnqIACy0xSyXHxjDOnQTYwhn8WcqUEJH0UL9ll5rVVTEUaYqNtvxVnr-q4W8P3Xumrib7otbVQD7_UM0aUSmgT6PZmDqNwWtMjaDExi7CzDivaT0k10WiyupMw9UNSBT9g4DrVn4KFpC_FdGZzReFApcxSmBroryHko5gO9R232TTSVWKG9Apo5TFZ_8g7Rzt-se6euQF2irnC3sJSKc0V5UufwNjMvax
  priority: 102
  providerName: Taylor & Francis
Title Non-pharmaceutical interventions to optimize cancer immunotherapy
URI https://www.tandfonline.com/doi/abs/10.1080/2162402X.2023.2255459
https://search.proquest.com/docview/2872805135
https://pubmed.ncbi.nlm.nih.gov/PMC10543347
https://doaj.org/article/c161ba4d3fa0448cb631e7f204bfecca
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6ygUIvpU-6bbq40Ku9kvWwdUxDw1JI6KGB7UlIXqkxdO1l4xzSX5-RbBe7l0KvY9kMM2PNN9I8AD7JcLtVMpsWxGCAQp1PFTN5mjtqjeTEljQUCl9dy80N_7oV2xOQYy1MTNqvbJ01v_ZZU9_G3MrDvlqPeWLrb1cXiAk4Y7xYL2CBFjqJ0fv9F516HCGW01AShBY8lu6UZB1oGDNtszA3PENrRgihZk4p9u7_q3PpDH_Osycn7ujyOTwbcGRy3vP7Ak5c8xKe9JMlH17B-XXbpIfb6Xl1Uk_SG--Srk1a3C729W-XVEH1x6QOtSJDRdbDa7i5_PL9YpMO0xLSCp12lxqLHAmMdL3f2YJUzHnmuRWyUMaKwsiAZUTuw5BPXGZKR5VD4o5TtbMuZ2_gtGkb9xYSIo0ivFKCWMuF8ApRi-D4ZaUqSmW5hGwUlz70TTE0HXqNjvLVQb56kO8SPgeh_lkcelpHQnv8qQfN6grBpzV8x7whGDRWVjLqCp8Tbn0wtCWoqUp0F480fD9_RLN_MPBx1J_G_ydcipjGtfd3GiPGvMSdiYkllDPFzridP0HDjJ24R0N89_-vvoengdG-d-QZnHbHe_cBcU5nV7AgPzareEqwiib-CAzY_Gw
link.rule.ids 230,315,730,783,787,867,888,2109,27514,27936,27937,53804,53806,59475,59476
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgQX3ojlGSSuydqxncTHUlEt0F1xaMXeLNtrtxFsstpmD-2vZ5wH2vSC4Go7ke0Z29_YM98AfMzC61bBTJwTjQYKdT6WTKdx6qjRGSemoCFQeL7IZuf861IsDyAbYmFap31ryqT6tU6q8rL1rdys7XTwE5t-nx8jJuCM8Xx6B-7igiV8z0rvdmA81tskYikNQUGow0PwTkGmoQytpmUSMocnqM8IIuToWGrZ-29xl44Q6Nh_cu9AOnkEP4ahdH4oP5NdYxJ7c4vl8d_H-hge9hg1Ourqn8CBq57CvS5r5fUzOFrUVby53L8Lj8o918mrqKmjGreidXnjIhvUahuVIQ6lj_a6fg7nJ5_Pjmdxn4khtggImlgbHKtAK9r7lcmJZc4zz43IcqmNyHUWcJJIfUggis104ah0WLjiVK6MS9kLOKzqyr2EiGRaEm6lIMZwIbxERCQ4_llKS2lWTCAZBKE2HeGGoj2P6SA5FSSneslN4FMQ15_GgS-7Lai3F6qfSWUR2BrNV8xrggapNRmjLvcp4cYHJZ6A3Be2atrrEt_lNlHsLx34MGiGwrUZHlx05erdlUJrNC1w12NiAsVIZUa9HdegIrQs34PgX_3_p-_h_uxsfqpOvyy-vYYHodMdR-UbOGy2O_cW8VRj3rWL5zexlRy2
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagFagXKC91gUKQuCaxYzuJj6V0VR5d9UCllThYtmPTCDZZ7WYP7a9nnAdKekHq1XEiOzNjf2PPfIPQx9TfbuVUhxlW4KAQ60JBVRImlmiVMqxz4hOFLxbp-RX7uuTLPqpy24dVVkaXUfVnFVXldRtbuV6ZeIgTiy8vTgETMEpZFq8LFz9E-2C0OB156t0qDFt7W0gsIT4xCPR4SODJcezbwHNaRr56eAQ6DUBCTLamlsH_Dn_pBIVOYyhHm9L8Kfo5TKeLRfkd7Rodmds7TI_3m-8hetJj1eCk6_MMPbDVc_Soq1558wKdLOoqXF-Pz8SDchRCuQ2aOqhhSVqVtzYwXr02QenzUfqsr5uX6Gp-9uP0POwrMoQGgEETKg3z5eBNO1foDBtqHXVM8zQTSvNMpR4v8cT5QqLQTeWWCAuNBSOi0Dahr9BeVVf2CAU4VQIzIzjWmnHuBCAjzuDLQhhC0nyGokEYct0Rb0jS85kO0pNeerKX3gx98iL719nzZrcN9eaX7P-mNABwtWIFdQqDY2p0SonNXIKZdl6ZZ0iMBS6b9tjEdTVOJP3PAD4M2iHBRv3Fi6psvdtK8EqTHFY_ymcon6jNZLTTJ6AMLdv3IPzX93_1PXp8-Xkuv39ZfHuDDvyYO6rKt2iv2ezsMcCqRr9r7ecvqlsfNg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non-pharmaceutical+interventions+to+optimize+cancer+immunotherapy&rft.jtitle=Oncoimmunology&rft.au=Boesch%2C+Maximilian&rft.au=Baty%2C+Florent&rft.au=Rassouli%2C+Frank&rft.au=Kowatsch%2C+Tobias&rft.date=2023-12-31&rft.pub=Taylor+%26+Francis&rft.issn=2162-4011&rft.eissn=2162-402X&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1080%2F2162402X.2023.2255459&rft.externalDBID=PMC10543347
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon